In vitro and in vivo studies on the stereoselective pharmacokinetics and biotransformation of an (S)-(–)- and (R)-(+)-pyrazolotriazine sulfoxide in the male rat

References

• BENOIT, E., BURONFOSSE, T. and DELATOUR, P., 1994, Effect of cytochrome P-450 1A induction on enantioselective metabolism and pharmacokinetics of an aryltrifluoromethyl sulfide in the rat. Chirafity, 6, 372–377.
   PubMed Web of Science ®Google Scholar
• BURONFOSSE, T., MORONI, P., BENOIT, E. and RIVIERE, J. L., 1995, Stereoselective sulfoxidation of the pesticide methiocarb by flavin-containing monooxygenase and cytochrome P450-dependent monooxygenases of rat liver microsomes: anticholinesterase activity of the two sulfoxide enantiomers. Journal of Biochemical Toxicology, 10, 179–189.
   PubMedGoogle Scholar
• IWAHARA, R., EMOTO, S., KAGA, J., ImuRA, Y., AOKI, M. and ASAKAWA, K., 1994, Chemical structure, physico- chemical properties and stability of sodium (1) -8- (3- methoxy-4-phenylsulfinyl-phenyl)pyrazolo[1,5-a]-1,3,5-triazine-4-olate monohydrate (B0E-4272). /yakuhin Kenkyu, 25, 426–438. [In Japanese]
   Google Scholar
• LOWRY, O. H., ROSEBROUGH, N. J., FAR, A. L. and RANDALL, R. J., 1951, Protein measurement with the Folin phenol reagent. Journal of Biological Chemistry, 193, 265–275.
   PubMed Web of Science ®Google Scholar
• MATSUGI, M., HASHIMOTO, K., Imm, M., FUKUDA, N., FURUTA, T., MINAMIKAWA, J. and OTSUKA, S., 1995, Asymmetric synthesis of a xanthine dehydrogenase inhibitor (S)-(-)-B0E-4272: utility of chiral alkoxysulfonium salts. Tetrahedron: Asymmetry, 6, 2991–3000.
   Google Scholar
• MOLDEUS, P., HOGBERG, J. and ORRENIU S., 1978, Isolation and use of liver cells. Methods in Enzymology, 52, 60–71.
   PubMedGoogle Scholar
• NAITO, S. and NISHIMURA, M., 1999, Pharmacokinetics and proposed metabolic pathways of BOF-4272, a sulphoxide-containing drug, based on in-vivo and in-vitro studies in rats. Pharmacy and Pharmacology Communications, 5, 123–131.
   Google Scholar
• NAITO, S., NISHIMURA, M. and Nouwww, H., 1999a, Pharmacokinetics of BOF-4272, a xanthine oxidase inhibitor, after single intravenous or oral administration to male mice and rats. Journal of Pharmacy and Pharmacology, 51, 347–351.
   PubMedGoogle Scholar
• NAITO, S., NISHIMURA, M., YOSHITSUGU, H. and NOGAWA, H., 1999b, Metabolic pathways and pharmacokinetics of BOF-4272, a sulfoxide-containing drug, in the dog: in vivo and in vitro studies. Biological and Pharmaceutical Bulletin, 22, 1391–1395.
   PubMedGoogle Scholar
• NISHIMURA, M., YAMAOKA, K., NArro, S. and NAKAGAWA, T., 1996, Hepatic local disposition of a drug with high protein binding and high hepatic clearance using BOF-4272 as a model drug. Biological and Pharmaceutical Bulletin, 19, 1197–1202.
   PubMedGoogle Scholar
• NISHIMURA, M., YAMAOKA, K., NAITO, S. and NAKAGAWA, T., 1997, Influence of albumin O.1 enantioselective local disposition of BOF-4272, a xanthine oxidase inhibitor with chiral sulfoxide, in rat liver. Biological and Pharmaceutical Bulletin, 20, 1285–1289.
   PubMedGoogle Scholar
• NISHIMURA, M., YAMAOKA, K., YAsui, H., NArro, S. and NAKAGAWA, T., 1994, Local disposition of new xanthine oxidase/xanthine dehydrogenase inhibitor, BOF-4272, in rat liver. Biological and Pharmaceutical Bulletin, 17, 1301–1304.
   PubMedGoogle Scholar
• NISHIMURA, M., YAMAOKA, K., YASUI, H., NArro, S. and NAKAGAWA, T., 1995, Effect of temperature in perfusate on local hepatic disposition of BOF-4272, a new xanthine oxidase inhibitor. Biological and Pharmaceutical Bulletin, 18, 980–983.
   PubMedGoogle Scholar
• OKAMOTO, K. and NISHINO, T., 1995, Mechanism of inhibition of xanthine oxidase with a new tight binding inhibitor. Journal of Biological Chemistry, 270, 7816–7821.
   PubMed Web of Science ®Google Scholar
• RETTIE, A. E., MEIER, G. P. and SADEQUE, A. J., 1995, Prochiral sulfides as in vitro probes for multiple forms of the flavin-containing monooxygenase. Chemico-Biological Interactions, 96, 3–15.
   PubMed Web of Science ®Google Scholar
• SATO, D., TATSUMI, K. and NISHINO, T., 1991, A novel xanthine dehydrogenase inhibitor, BOF-4272. Advances in Experimental Medicine and Biology, 309A, 135–138.
   PubMedGoogle Scholar
• SUZUKI, H., SUEMATSU, M., ISHII, H., KATO, S., MIKI, H., Mom, M., ISHIMIURA, Y., NISHINO, T. and TSUCHIYA, M., 1994, Prostaglandin Ej abrogates early reductive stress and zone-specific paradoxical oxidative injury in hypoperfused rat liver. Journal of Clinical Investigation, 93, 155–164.
   PubMed Web of Science ®Google Scholar
• TERAO, T., MATSUBARA, T., KAGA, J., KOBATAKE, H. and NAITO, S., 1995, Improvement of gastrointestinal absorption of a new oral xanthine oxidase/dehydrogenase inhibitor, sodium (±)-8- (3- methoxy- 4-phe nylsulfinylphenyh-pyrazolo [1, 5-a] -1, 3,5-triazine -4- olatc monohydrate, in rats and dogs. Yakuzaigaku, 55, 36–43. [In Japanese]
   Google Scholar
• UEMATSU, T. and NAKASHIMA, M., 1994, Pharmacokinetic and pharmacodynamic properties of a novel xanthine oxidase inhibitor, BOF-4272, in health volunteers. Journal of Pharmacology and Experimental Therapeutics, 270, 453–459.
   PubMed Web of Science ®Google Scholar
• YAMAMOTO, T., MORIWAKI, Y., SUDA, M., NASAKO, Y., TAKAHASHI, S., HIROISHI, K., NAKANO, T., HADA, T. and HIGASHINO, K., 1993, Effect of BOF-4272 on the oxidation of allopurinol and pyrazinamide in vivo. Is xanthine dehydrogenase or aldehyde oxidase more important in oxidizing both allopurinol and pyrazinamide? Biochemical Pharmacology, 46, 2277–2284.
   Google Scholar
• YAMAOKA, K., NAKAGAWA, T. and UNO, T., 1978, Statistical moments in pharmacokinetics. Journal of Pharmacokinetics and Biopharmaceutics, 6, 547–558.
   PubMedGoogle Scholar